| Axon ID |
Name |
Description |
From price |
|
1338
|
CP 690550
|
JAK3 inhibitor |
€60.00 |
|
1378
|
AG 490
|
JAK2 inhibitor |
€65.00 |
|
1588
|
TG 101348
|
JAK2 inhibitor |
€80.00 |
|
1598
|
Ruxolitinib
|
JAK1 and JAK2 inhibitor |
€65.00 |
|
1681
|
CYT 387
|
JAK1 and JAK2 inhibitor |
€90.00 |
|
1778
|
AZ 960
|
JAK2 inhibitor |
€95.00 |
|
1843
|
JAK2 inhibitor 13
|
JAK2 inhibitor |
€110.00 |
|
1955
|
Baricitinib
|
Inhibitor of JAK1 and JAK2 |
€70.00 |
|
1992
|
AS 1517499
|
Potent and selective STAT6 inhibitor |
€130.00 |
|
2072
|
Tofacitinib citrate
|
Potent Janus Kinase 3 (JAK3) inhibitor |
€115.00 |
|
2141
|
ABT 199
|
Potent, orally bioavailable BCL-2-selective inhibitor |
€70.00 |
|
2217
|
PF 956980
|
JAK3 inhibitor; analogue of Axon 1338 and 2072 |
€90.00 |
|
2219
|
AT 9283
|
Multitargeted kinase inhibitor (Aurora A/B, JAK2/3, and BCR-Abl) |
€85.00 |
|
2231
|
XL 019
|
JAK2 inhibitor |
€100.00 |
|
2314
|
Stattic
|
Nonpeptidic small-molecule inhibitor of STAT3 activation, dimerization, and nuclear translocation |
€50.00 |
|
2489
|
Brassinin
|
Dual IDO1/STAT3 inhibitor with antifungal and anticancer activity |
€75.00 |
|
2517
|
Napabucasin
|
Oral first-in-class cancer stemness inhibitor that works by targeting STAT3 |
€105.00 |
|
2539
|
Solcitinib
|
Selective JAK1 inhibitor for treatment of degenerative and inflammatory diseases |
€90.00 |
|
2554
|
LY 2784544
|
Potent, selective and ATP-competitive inhibitor of mutated janus kinase 2 (JAK2V617F) |
€95.00 |
|
2792
|
NVP-BSK805
|
Potent, selective and orally bioavailable JAK2 inhibitor |
€125.00 |
|
2775
|
Cerdulatinib
|
Orally active dual Syk/JAK inhibitor |
€85.00 |
|
3671
|
CEP-33779
|
Potent, selective and orally bioavailable JAK2 inhibitor |
€95.00 |
|
3766
|
DT-2216
|
Selective B-cell lymphoma-extra large (Bcl-XL) targeted protein degrader |
Inquire |
|
3786
|
BP-1-102
|
Orally bioavailable STAT3 inhibitor |
€90.00 |
|
3813
|
BMS-911543
|
Potent, selective and orally active inhibitor of JAK2 |
Inquire |
|
3814
|
AZD4320
|
BH3-mimetic inhibitor of BCL-2 protein |
Inquire |
|
3821
|
ABT-263
|
Potent, selective and orally bioavailable inhibitor of B-cell lymphoma-2 (BCL-2) family proteins |
Inquire |
|
3855
|
AZD-4205
|
Selective and ATP-competitive inhibitor of JAK1 |
Inquire |
|
3834
|
Alantolactone
|
STAT3 inhibitor; NLRP3 inhibitor |
€90.00 |
|
3950
|
Peficitinib
|
Potent and orally bioavailable JAK inhibitor |
Recently added
|
€120.00 |
|
3997
|
ASN-002
|
Potent dual inhibitor of SYK and pan-JAK kinases |
Recently added
|
Inquire |
|
4006
|
GLPG-0634
|
The first orally-available, selective inhibitor of JAK1 |
Recently added
|
Inquire |